Trials / Completed
CompletedNCT02223351
Drug-Drug Interaction Study: ASP2151 and Ritonavir
A Single-centre, Open-label, Randomised, Crossover, Drug-drug Interaction Study to Investigate the Effect of a Single Oral Dose of Ritonavir on the Single Dose Pharmacokinetics of ASP2151 in Healthy Men
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Maruho Europe Limited · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
ASP2151 is an experimental treatment for herpes. HIV infected people are susceptible to contracting other infections because of their compromised immune system. As HIV patients will be taking drugs to treat the virus this study aims to see if ASP2151 would interact with one of the drugs that is commonly prescribed to HIV patients (ritonavir).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASP2151 | |
| DRUG | ritonavir |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2014-12-01
- Completion
- 2014-12-01
- First posted
- 2014-08-22
- Last updated
- 2019-02-27
- Results posted
- 2019-01-11
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02223351. Inclusion in this directory is not an endorsement.